The findings illustrate that even if such algorithms are ready for primetime, providers have work to do convincing patients of their efficacy, Dutch experts noted.

Clinicians have long relied on x-ray and MRI to diagnose the condition, but both fall short in detecting subtle molecular changes.

German researchers reported success using Cerenkov luminescence imaging in 10 patients, according to a first-in-human study published in the Journal of Nuclear Medicine.

As part of the endeavor, the Lou Ruvo Center for Brain Health will utilize advanced imaging techniques, such as diffusion-weighted MRI.

Imaging experts from two top institutions detailed five factors to consider prior to pulling the trigger.

The company, Abridge, aims to help patients gain a better understanding of their own healthcare. 

Patients typically wait a while to understand if their treatment is working, but this imaging approach could reduce that time and help personalize care.

If providers can detect CHD before a child is born, doctors can begin life-saving care immediately after birth.